Lonza Completes Divestment of Two Sites to NextPharma

• Completion of sale of Lonza sites in Ploermel (FR) and Edinburgh (UK)
• A seamless ownership transfer process remains a priority

Quote from Gordon Bates, President and Head of Small Molecules, Lonza:

“The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies. In this context, as we close the divestment process, we are confident that NextPharma is well placed to develop and grow both sites to their full potential. We wish to thank the leadership teams and employees at the Ploermel and Edinburgh sites for their continuing dedication and professionalism during the transition period.”

Quote from Peter Burema, CEO of NextPharma:

“We are very excited at adding two new centers of excellence, at Ploermel and Edinburgh, to NextPharma’s manufacturing network, allowing us to further broaden our technology offering for both our existing and new customers. These technologies, combined with the know-how and expertise of the employees at both sites, will provide additional solutions for drug formulations which will benefit patients across the world. On behalf of the whole NextPharma team, I welcome our new colleagues, and together we look forward to continuing to further develop and grow NextPharma as a leading and well-respected European CDMO.”

Basel, Switzerland and London, United Kingdom, 1 April 2021 – Lonza announced today the completion of the divestment of its Ploermel (FR) and Edinburgh (UK) sites to NextPharma.

The agreement between both parties was previously announced on 19 January 2021.

About NextPharma

NextPharma is a leading European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with a current footprint spanning five sites in Germany, one in France and one in Finland, and with healthcare logistics services in the DACH region. NextPharma supplies products globally, with six of its seven sites FDA-approved. With expertise in solids, semi solids and non-sterile and sterile liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms including tablets, capsules, granules, powders, pellets, gels, creams, sprays and syrups. Additionally, it provides a wide range of packaging solutions including blow-fill-seal, blisters, bottles, sachets, stick packs and tubes. NextPharma’s expertise and centres of excellence enable it to provide a unique service offering in certain very specific specialised areas such as hormonal solids and semi-solids, cephalosporins, penicillins, narcotics, modified release products, ophthalmics as well as paediatric medicinal products. For more information, please visit www.nextpharma.com.

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.